keyword
https://read.qxmd.com/read/38493107/a-matter-of-differentiation-equine-enteroids-as-a-model-for-the-in-vivo-intestinal-epithelium
#1
JOURNAL ARTICLE
Christina Windhaber, Anna Heckl, Georg Csukovich, Barbara Pratscher, Iwan Anton Burgener, Nora Biermann, Franziska Dengler
Epithelial damage due to gastrointestinal disorders frequently causes severe disease in horses. To study the underlying pathophysiological processes, we aimed to establish equine jejunum and colon enteroids (eqJE, eqCE) mimicking the in vivo epithelium. Therefore, enteroids were cultivated in four different media for differentiation and subsequently characterized histomorphologically, on mRNA and on protein level in comparison to the native epithelium of the same donor horses to identify ideal culture conditions for an in vitro model system...
March 16, 2024: Veterinary Research
https://read.qxmd.com/read/38479036/the-efficacy-and-safety-of-aspirin-ticagrelor-vs-aspirin-clopidogrel-in-ischemic-stroke-patients-with-cerebral-artery-stenting
#2
JOURNAL ARTICLE
Chenxi Liu, Mingsu Liu, Xun Yang, Tingting Luo, Jinping Wang, Guangqin Li
OBJECTIVE: First, the efficacy and safety of aspirin-ticagrelor after cerebral artery stenting in ischemic stroke patients is controversial. Second, there is a gap in the research on guiding two antiplatelet therapy (DAPT) after stenting based on the CYP2C19 genotype. METHODS: This retrospective study included patients who underwent cerebral artery stenting at the First Affiliated Hospital of Chongqing Medical University from January 2019 to February 2023. We divided them into the aspirin-clopidogrel group and aspirin-ticagrelor group and carefully collected baseline information laboratory data and imaging results from the patients...
March 3, 2024: Clinical Neurology and Neurosurgery
https://read.qxmd.com/read/38471248/bleeding-complications-coagulation-disorders-and-their-management-in-acute-myocardial-infarction-related-cardiogenic-shock-rescued-by-veno-arterial-ecmo-a-retrospective-cohort-study
#3
JOURNAL ARTICLE
Paul Masi, Ségolène Gendreau, Quentin Moyon, Maxence Leguyader, Guillaume Lebreton, Jacques Ropers, Laurence Dangers, Samuel Sitruk, Nicolas Bréchot, Marc Pineton de Chambrun, Juliette Chommeloux, Matthieu Schmidt, Charles Edouard Luyt, Pascal Leprince, Alain Combes, Corinne Frere, Guillaume Hékimian
PURPOSE: Management of dual antiplatelet therapy (DAPT) in patients on venoarterial-extracorporeal membrane (VA-ECMO) after acute myocardial infarction (AMI) is challenging. Our objective was to describe the frequency, management and outcomes of severe bleeding complications and determine their occurrence risk factors. MATERIAL AND METHODS: We conducted a retrospective observational cohort study including post-AMI cardiogenic shock patients requiring VA-ECMO. Severe bleeding was defined based on the Bleeding Academic Research Consortium classification...
March 11, 2024: Journal of Critical Care
https://read.qxmd.com/read/38465531/antiplatelet-treatment-preferences-of-a-group-of-cardiologists-from-t%C3%A3-rkiye-a-survey-research-study
#4
JOURNAL ARTICLE
Özge Çetinarslan, Mustafa Yenerçağ, Mehdi Zoghi, Asım Oktay Ergene
OBJECTIVE: Deciding on the optimal duration of dual antiplatelet treatment (DAPT) remains a complex decision. This survey aims to explore the preferences for antiplatelet therapy and the daily routine regarding DAPT duration in coronary artery disease among a group of cardiologists in Türkiye. METHOD: Using an online questionnaire with 38 questions, the preferences of 314 cardiologists were collected. Qualitative descriptive characteristics of the answers received from the participants were examined...
March 2024: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://read.qxmd.com/read/38460814/optimizing-dual-antiplatelet-therapy-in-the-perioperative-period-for-spine-surgery-after-recent-percutaneous-coronary-intervention-a-comprehensive-review-synthesis-and-catalyst-for-protocol-formulation
#5
REVIEW
Noelle Lucke-Wold, Grace Hey, Angela Rivera, Danyas Sarathy, Rogina Rezk, Andrew MacNeil, Ashley Albright, Brandon Lucke-Wold
The increased incidence of spine surgery within the last decade has highlighted the importance of robust perioperative management to improve patient outcomes overall. Coronary artery disease (CAD) is a common medical comorbidity present in the population of individuals who receive surgery for spinal pathology that is often treated with dual-antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). Discontinuation of DAPT prior to surgical intervention is typically indicated, however, contradictory evidence exists in the literature regarding the timing of DAPT use and discontinuation in the perioperative period...
March 7, 2024: World Neurosurgery
https://read.qxmd.com/read/38458371/ticagrelor-with-or-without-aspirin-following-percutaneous-coronary-intervention-in-high-risk-patients-with-concomitant-peripheral-artery-disease-a-subgroup-analysis-of-the-twilight-randomized-clinical-trial
#6
JOURNAL ARTICLE
Mitchell Krucoff, Alessandro Spirito, Usman Baber, Samantha Sartori, Dominick J Angiolillo, Carlo Briguori, David J Cohen, Timothy Collier, George Dangas, Dariusz Dudek, Javier Escaned, C Michael Gibson, Ya-Ling Han, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Vijay Kunadian, Birgit Vogel, Shamir R Mehta, David Moliterno, Gennaro Sardella, Richard A Shlofmitz, Samin Sharma, Philippe Gabriel Steg, Stuart Pocock, Roxana Mehran
BACKGROUND: The optimal antiplatelet regimen after percutaneous coronary intervention (PCI) in patients with peripheral artery disease (PAD) is still debated. This analysis aimed to compare the effect of ticagrelor monotherapy versus ticagrelor plus aspirin in patients with PAD undergoing PCI. METHODS: In the TWILIGHT trial, patients at high ischemic or bleeding risk that underwent PCI were randomized after 3 months of dual antiplatelet therapy (DAPT) to aspirin or matching placebo in addition to open-label ticagrelor for 12 additional months...
March 6, 2024: American Heart Journal
https://read.qxmd.com/read/38458235/de-escalation-versus-shortening-of-dapt
#7
JOURNAL ARTICLE
Mattia Galli, Francesco Costa, Eliano Pio Navarese
No abstract text is available yet for this article.
March 8, 2024: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/38451525/p2y12-inhibitor-monotherapy-vs-dual-antiplatelet-therapy-after-deployment-of-a-drug-eluting-stent-the-share-randomized-clinical-trial
#8
RANDOMIZED CONTROLLED TRIAL
Pil-Ki Min, Tae Soo Kang, Yun-Hyeong Cho, Sang-Sig Cheong, Byeong-Keuk Kim, Sung Woo Kwon, Woo Jung Park, Jung-Hee Lee, Wonho Kim, Wang-Soo Lee, Young Won Yoon, Byoung Kwon Lee, Hyuck Moon Kwon, Bum-Kee Hong
IMPORTANCE: P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutaneous coronary intervention (PCI) with a drug-eluting stent. OBJECTIVE: To investigate whether P2Y12 inhibitor monotherapy after 3 months of DAPT was noninferior to 12 months of DAPT following PCI with a drug-eluting stent. DESIGN, SETTING, AND PARTICIPANTS: The Short-Term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-Eluting Stent (SHARE) open-label, noninferiority randomized clinical trial was conducted from December 15, 2017, through December 14, 2020...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38448665/reprogramming-of-astrocytes-to-neuronal-like-cells-in-spinal-cord-injury-a-systematic-review
#9
REVIEW
Seyed Danial Alizadeh, Mohammad-Rasoul Jalalifar, Zahra Ghodsi, Mohsen Sadeghi-Naini, Hamid Malekzadeh, Golnoosh Rahimi, Kurosh Mojtabavi, Sina Shool, Zahra Eskandari, Rasoul Masoomi, Sahar Kiani, James Harrop, Vafa Rahimi-Movaghar
STUDY DESIGN: A Systematic Review OBJECTIVES: To determine the therapeutic efficacy of in vivo reprogramming of astrocytes into neuronal-like cells in animal models of spinal cord injury (SCI). METHODS: PRISMA 2020 guidelines were utilized, and search engines Medline, Web of Science, Scopus, and Embase until June 2023 were used. Studies that examined the effects of converting astrocytes into neuron-like cells with any vector in all animal models were included, while conversion from other cells except for spinal astrocytes, chemical mechanisms to provide SCI models, brain injury population, and conversion without in-vivo experience were excluded...
March 6, 2024: Spinal Cord
https://read.qxmd.com/read/38447449/the-bone-protective-benefits-of-kaempferol-combined-with-metformin-by-regulation-of-osteogenesis-angiogenesis-coupling-in-ovx-rats
#10
JOURNAL ARTICLE
Zhongyuan Zhang, Wenshu Xu, Zhenhua Zhang, Xiaoxue Chen, Hui Jin, Ningning Jiang, Hui Xu
This study was to investigate the potential mechanisms of treatment with metformin (Met) combined with kaempferol (Kae) against postmenopausal osteoporosis. Experiments were conducted in both ovariectomy (OVX)-induced osteoporosis rats and in vitro using RAW264.7 cells, MC3T3-E1 cells, and HUVECs. Results demonstrated the therapeutic effect of Met combined with Kae on osteoporosis. In vivo, Kae alone and in combination with Met treatments enhanced tibial trabecular microstructure, bone mineral density (BMD), and mechanical properties in OVX rats without causing hepatotoxicity and nephrotoxicity...
March 5, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38447421/impact-of-very-low-dose-rivaroxaban-in-addition-to-dual-antiplatelet-therapy-on-endogenous-fibrinolysis-in-acute-coronary-syndrome-the-validate-r-study
#11
JOURNAL ARTICLE
Ying X Gue, Vassilios Memtsas, Rahim Kanji, David M Wellsted, Amanda Busby, Megan Smith, Enric Vilar, Alisdair Ryding, Deepa J Arachchillage, Diana A Gorog
BACKGROUND: Impaired endogenous fibrinolysis is adverse cardiovascular risk factor in acute coronary syndrome (ACS) patients. Addition of very low dose rivaroxaban (VLDR) to dual antiplatelet therapy (DAPT) reduces cardiovascular events but increases bleeding. OBJECTIVE: We aimed to assess whether addition of VLDR to DAPT can enhance endogenous fibrinolysis. METHODS: In a prospective, open-label trial, we assessed endogenous fibrinolysis in whole blood, in 549 patients with ACS using the Global Thrombosis Test (GTT) and Thromboelastography (TEG)...
March 3, 2024: Thrombosis Research
https://read.qxmd.com/read/38444491/dang-gui-bu-xue-decoction-improves-wound-healing-in-diabetic-rats-by-the-activation-of-notch-signaling
#12
JOURNAL ARTICLE
Xian Zhang, Song Zhao, Xiaogui Zhao, Zhiwei Yang, Xiaodan Wang
Diabetes serves as a severe chronic disease that severely affects the normal life of human beings. Diabetes causes the complication of diabetic wound dysfunction, which is characterized by sustained inflammation, altered angiogenesis, delayed epithelialization and abnormal secretion of protease. Dang-Gui-Bu-Xue decoction (DBD) is a Chinese traditional medicine that comprises Radix Astragali and Radix Angelicae sinensis and is widely applied in treatment of multiple diseases owing to its functions against inflammation, lipid peroxidation and oxidative stress...
March 15, 2024: Heliyon
https://read.qxmd.com/read/38441042/optimizing-platelet-inhibition-in-peripheral-artery-disease-a-comparison-of-mono-antiplatelet-therapy-and-dual-antiplatelet-therapy-using-thromboelastography
#13
JOURNAL ARTICLE
Ivy Lee, Sasha Suarez, Ryan Hall, Monica Majumdar, Tiffany Bellomo, Samuel Jessula, Kathryn Nuzzolo, Douglas M Jefferson, Nikolaos Zacharias, Anahita Dua
BACKGROUND: Antiplatelet therapy is used to prevent thrombosis in patients with peripheral artery disease (PAD) following revascularization. However, the current standard of care for these patients remains at the physician's discretion, varying from mono-antiplatelet therapy (MAPT) to dual-antiplatelet therapy (DAPT). Viscoelastic assays such as Thromboelastography with Platelet Mapping (TEG-PM) provide insight into individual coagulation profiles and measure real-time platelet function...
March 5, 2024: Vascular
https://read.qxmd.com/read/38439698/clopidogrel-versus-newer-p2y12-inhibitors-in-the-dual-antiplatelet-therapy-for-stent-assisted-coil-embolization-of-intracranial-aneurysms-a-meta-analysis
#14
REVIEW
Sávio Batista, Raphael Camerotte, Agostinho C Pinheiro, Igor Costermani, Anthony Bishay, José Alberto Almeida Filho, Lucca B Palavani, Edmundo Damiani Bertoli, Raphael Bertani, Jason A Ellis, Yafell Serulle, Christian Ferreira
INTRODUCTION: Stent-assisted coil embolization (SACE) for cerebral aneurysms requires dual antiplatelet therapy (DAPT), commonly clopidogrel plus aspirin is preferable to ticagrelor or prasugrel plus aspirin. However, there are few studies assessing the safety of the association of ticagrelor or prasugrel plus aspirin. OBJECTIVES: Compare the safety of newer P2Y12 inhibitors with clopidogrel in patients that underwent a SACE for cerebral aneurysms. METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, we searched PubMed and Embase for studies comparing newer P2Y12 inhibitors with clopidogrel in patients undergoing DAPT for SACE...
March 5, 2024: Interventional Neuroradiology
https://read.qxmd.com/read/38436990/ldl-c-levels-and-bleeding-risk-in-patients-taking-dapt-after-minor-ischemic-stroke-or-tia
#15
JOURNAL ARTICLE
Aichun Cheng, Jing Xue, Anxin Wang, Qin Xu, Zhiyuan Feng, Jinxi Lin, Hao Li, Xia Meng, Jie Xu, Yongjun Wang
IMPORTANCE: Evidence on the bleeding risk associated with low-density lipoprotein cholesterol (LDL-C) levels in patients receiving dual antiplatelet therapy (DAPT) remains sparse. OBJECTIVE: To investigate the association of LDL-C levels with bleeding risk in patients with minor ischemic stroke (MIS) or high-risk transient ischemic attack (HRTIA) receiving DAPT. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was an analysis of pooled data from 2 randomized, double-blind, placebo-controlled clinical trials in China of patients with MIS or HRTIA who were receiving DAPT: the CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) trial enrolled patients at 114 sites from October 2009 to July 2012, and the CHANCE-2 enrolled patients at 202 centers from September 2019 to March 2021...
March 4, 2024: JAMA Neurology
https://read.qxmd.com/read/38436365/one-month-dapt-with-ticagrelor-and-aspirin-for-patients-undergoing-coronary-artery-bypass-grafting-rationale-and-design-of-the-randomised-multicentre-double-blind-placebo-controlled-odin-trial
#16
RANDOMIZED CONTROLLED TRIAL
Sigrid Sandner, Mario Gaudino, Bjorn Redfors, Dominick J Angiolillo, Ori Ben-Yehuda, Deepak L Bhatt, Stephen E Fremes, Andre Lamy, Riccardo Marano, Roxana Mehran, Stuart Pocock, Sunil V Rao, John A Spertus, Jonathan W Weinsaft, George Wells, Marc Ruel
The optimal antiplatelet strategy after coronary artery bypass graft (CABG) surgery in patients with chronic coronary syndromes (CCS) is unclear. Adding the P2Y12 inhibitor, ticagrelor, to low-dose aspirin for 1 year is associated with a reduction in graft failure, particularly saphenous vein grafts, at the expense of an increased risk of clinically important bleeding. As the risk of thrombotic graft failure and ischaemic events is highest early after CABG surgery, a better risk-to-benefit profile may be attained with short-term dual antiplatelet therapy followed by single antiplatelet therapy...
March 4, 2024: EuroIntervention
https://read.qxmd.com/read/38428900/time-interval-of-esomeprazole-and-dual-antiplatelet-therapy-in-patients-with-cardiocerebrovascular-diseases
#17
JOURNAL ARTICLE
Hyunsoo Kim, Moon-Hwa Park, Joon-Tae Kim
Dual antiplatelet therapy (DAPT) with the combination of clopidogrel and aspirin is recommended for preventing secondary ischemic events in patients with acute coronary syndrome (ACS) or acute ischemic stroke (AIS). Proton pump inhibitors (PPIs) are suggested as preventive treatment for these patients. Due to clopidogrel-PPI interactions, separating their administration might be considered. However, a paucity of studies has been conducted to investigate the outcome differences between concurrent and interval-based use in ACS and AIS patients...
March 1, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38423578/management-conundrum-in-a-case-of-renal-cell-cancer-rcc-on-dual-antiplatelet-therapy-dapt-for-recently-placed-coronary-drug-eluting-stent-des
#18
JOURNAL ARTICLE
Rudra Prasad Ghorai, Sridhar Panaiyadiyan, Prabhjot Singh, Brusabhanu Nayak
A man in his 50s presented in an emergency with breathlessness and chest discomfort. On evaluation, he was diagnosed with coronary artery disease, with more than 80% narrowing of the right coronary and left circumflex arteries. The patient underwent percutaneous coronary intervention and was started on dual antiplatelet (DAPT) therapy. After starting DAPT, the patient developed gross haematuria with a drop in haematocrit. Further evaluation revealed a left renal mass with urinary bladder clots. Because of the risk of stent thrombosis on stopping DAPT, radical nephrectomy was deferred, and the patient underwent left renal artery angioembolisation and bladder clot evacuation...
February 29, 2024: BMJ Case Reports
https://read.qxmd.com/read/38417575/salidroside-promotes-pro-angiogenesis-and-repair-of-blood-brain-barrier-via-notch-itgb1-signal-path-in-csvd-model
#19
JOURNAL ARTICLE
Tu Zhilan, Zhang Zengyu, Jin Pengpeng, Yang Hualan, Li Chao, Xi Yan, Guo Zimin, Hou Shuangxing, Li Weiwei
INTRODUCTION: Salidroside (SAL), extracted from Rhodiola rosea, has been widely used in coronary heart disease and myocardial ischemia for decades. Previous studies have demonstrated that SAL could reduce arteriosclerosis, and thus combat ischemic brain damage. However, the in-depth function of the salidroside in Cerebral Small Vascular Disease (CSVD) has not been discovered, and related molecular mechanism is still unclear. OBJECTIVES: The present study aims to explore the effects of salidroside in angiogenesis as well as repair of blood brain barrier (BBB) and its possible mechanisms...
February 28, 2024: Journal of Advanced Research
https://read.qxmd.com/read/38417246/dual-antiplatelet-therapy-after-intravenous-thrombolysis-for-patients-with-minor-ischemic-stroke%C3%AF-a-meta-analysis
#20
JOURNAL ARTICLE
Jing Zeng, Wenli Xin, Shuang Tang, Chengwei Xiang, Chun Zeng
OBJECTIVE: Intravenous thrombolysis (IVT) has been shown to effectively decrease both the disability rate and mortality associated with acute ischemic stroke, however, there is also a risk of vascular re-occlusion. Antiplatelet therapy can mitigate this risk. Nevertheless, there are no relevant guidelines recommending whether the administration of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel can be performed following thrombolysis. The aim of this study was to conduct a meta-analysis utilizing multiple studies in order to assess the effectiveness and safety of DAPT after IVT in cases of acute mild ischemic stroke (AMIS)...
March 2024: Clinical Neurology and Neurosurgery
keyword
keyword
18118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.